Profile: OccuLogix, Inc. (TEAR.O)

OccuLogix, Inc. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). The TearLab Osmolarity System enables the rapid measurement of tear osmolarity in the doctor's office, a quantitative and highly specific biomarker that has been shown to correlate with DED. On October 6, 2008, the Company acquired the remaining minority interest in TearLab, Inc.

The TearLab Osmolarity System consists of the three components: the TearLab disposable, which is a single-use microfluidic labcard; the TearLab pen, which is a hand-held device that interfaces with the TearLab disposable, and the TearLab reader, which is a small desktop unit that allows for the docking of the TearLab disposable and the TearLab pen and provides a quantitative reading for the operator. In October 2008, the TearLab Osmolarity System received CE mark approval, clearing the way for sales in the European Union and all countries recognizing the CE mark.